|
WO2020232408A1
|
|
Treatment methods
|
|
WO2020092379A1
|
|
Treatment methods
|
|
WO2020069454A1
|
|
Treatment methods
|
|
CA3113259A1
|
|
Treatment methods
|
|
EP3601536A1
|
|
Treatment methods
|
|
WO2018064232A1
|
|
Methods and compositions for treating herpes
|
|
WO2014018904A1
|
|
Fused antigen vaccines and compositions against streptococcus pneumoniae
|
|
WO2013134656A1
|
|
Induction of th17 immune response
|
|
EP2804627A2
|
|
Fused antigen vaccines and compositions against streptococcus pneumoniae
|
|
CA2885693A1
|
|
Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
|
SG192060A1
|
|
Vaccines and compositions against streptococcus pneumoniae
|
|
CA2856697A1
|
|
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
|
WO2012054755A1
|
|
Chlamydia antigens and uses thereof
|
|
CA2803061A1
|
|
Vaccines and compositions against streptococcus pneumoniae
|
|
CN106924728A
|
|
For the vaccine of herpes simplex virus type 2：Induce the composition and method of immune response
|
|
WO2010078027A1
|
|
Chlamydia antigens and uses thereof
|
|
EP2300828A1
|
|
Antigen screening system
|
